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Insulin induces drug resistance in melanoma through activation of the
PI3K/Akt pathway
Abstract

Introduction: There is currently no curative treatment for melanoma once the disease spreads beyond the
original site. Although activation of the PI3K/Akt pathway resulting from genetic mutations and epigenetic
deregulation of its major regulators is known to cause resistance of melanoma to therapeutic agents, including
the conventional chemotherapeutic drug dacarbazine and the Food and Drug Administration-approved
mutant BRAF inhibitors vemurafenib and dabrafenib, the role of extracellular stimuli of the pathway, such as
insulin, in drug resistance of melanoma remains less understood. Objective: To investigate the effect of insulin
on the response of melanoma cells to dacarbazine, and in particular, the effect of insulin on the response of
melanoma cells carrying the BRAFV600E mutation to mutant BRAF inhibitors. An additional aim was to
define the role of the PI3K/Akt pathway in the insulin-triggered drug resistance. Methods: The effect of
insulin on cytotoxicity induced by dacarbazine or the mutant BRAF inhibitor PLX4720 was tested by preincubation of melanoma cells with insulin. Cytotoxicity was determined by the MTS assay. The role of the
PI3K/Akt pathway in the insulin-triggered drug resistance was examined using the PI3K inhibitor LY294002
and the PI3K and mammalian target of rapamycin dual inhibitor BEZ-235. Activation of the PI3K/Akt
pathway was monitored by Western blot analysis of phosphorylated levels of Akt. Results: Recombinant
insulin attenuated dacarbazine-induced cytotoxicity in both wild-type BRAF and BRAFV600E melanoma
cells, whereas it also reduced killing of BRAFV600E melanoma cells by PLX4720. Nevertheless, the
protective effect of insulin was abolished by the PI3K and mTOR dual inhibitor BEZ-235 or the PI3K
inhibitor LY294002. Conclusion: Insulin attenuates the therapeutic efficacy of dacarbazine and PLX4720 in
melanoma cells, which is mediated by activation of the PI3K/Akt pathway and can be overcome by PI3K
inhibitors.
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Introduction: There is currently no curative treatment for melanoma once the disease spreads
beyond the original site. Although activation of the PI3K/Akt pathway resulting from genetic
mutations and epigenetic deregulation of its major regulators is known to cause resistance of
melanoma to therapeutic agents, including the conventional chemotherapeutic drug dacarbazine
and the Food and Drug Administration-approved mutant BRAF inhibitors vemurafenib and
dabrafenib, the role of extracellular stimuli of the pathway, such as insulin, in drug resistance
of melanoma remains less understood.
Objective: To investigate the effect of insulin on the response of melanoma cells to dacarbazine,
and in particular, the effect of insulin on the response of melanoma cells carrying the BRAFV600E
mutation to mutant BRAF inhibitors. An additional aim was to define the role of the PI3K/Akt
pathway in the insulin-triggered drug resistance.
Methods: The effect of insulin on cytotoxicity induced by dacarbazine or the mutant BRAF
inhibitor PLX4720 was tested by pre-incubation of melanoma cells with insulin. Cytotoxicity
was determined by the MTS assay. The role of the PI3K/Akt pathway in the insulin-triggered
drug resistance was examined using the PI3K inhibitor LY294002 and the PI3K and mammalian
target of rapamycin dual inhibitor BEZ-235. Activation of the PI3K/Akt pathway was monitored
by Western blot analysis of phosphorylated levels of Akt.
Results: Recombinant insulin attenuated dacarbazine-induced cytotoxicity in both wild-type
BRAF and BRAFV600E melanoma cells, whereas it also reduced killing of BRAFV600E melanoma
cells by PLX4720. Nevertheless, the protective effect of insulin was abolished by the PI3K and
mTOR dual inhibitor BEZ-235 or the PI3K inhibitor LY294002.
Conclusion: Insulin attenuates the therapeutic efficacy of dacarbazine and PLX4720 in melanoma cells, which is mediated by activation of the PI3K/Akt pathway and can be overcome
by PI3K inhibitors.
Keywords: insulin, PI3K/Akt, melanoma, drug resistance, DTIC, BRAF inhibitors
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Melanoma is one of the most aggressive cancers. Although early stages of melanoma
can be removed by surgery with high patient survival rates, metastatic melanoma has
poor prognosis. Despite recent progress in the treatment of late-stage melanoma, and in
particular, the advance in development of novel targeted therapy and immunotherapy
approaches, the overall outcome of patients with metastatic melanoma remains poor.1
The median survival period of these patients is about 6 to 10 months, and the 5-year
survival rate is lower than 20%.2,3 Therefore, it is of paramount importance to improve the
therapeutic efficacy of treatments for metastatic melanoma. This could be achieved either
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by improving already existing Food and Drug Administrationapproved drugs or by developing novel therapeutic agents.
Dacarbazine (DTIC) is the most commonly used chemotherapeutic drug in the treatment of metastatic melanoma.4
However, only 5%–10% of patients benefit from administration of DTIC.5 The mechanisms responsible for resistance of
melanoma cells to DTIC remain undefined, but combinations
of DTIC with other agents have been attempted to increase
the therapeutic efficacy. A Phase III clinical trial showed that
DTIC in combination with cisplatin or vindesine increased
the response rate to 20%–40%.6 However, disease-free and
overall survival rates were not increased.7 The combination of
DTIC with interleukin-2 or tumor-necrosis-factor-α improved
the response rate, but adverse effects were also increased.8
Cancer-targeted therapy is based on an understanding
of the roles of key molecules in the cancer pathogenesis.
Activating BRAF mutations that drive melanoma cell survival
and proliferation are found in about 60% of melanomas.
The most common mutation in melanoma is a glutamic
acid substitution for valine at position 600 (BRAFV600E).9,10
Targeting mutant BRAF using small molecule inhibitors, such
as vemurafenib and dabrafenib has achieved unprecedented
responses in metastatic melanoma patients.11–13 However,
complete remission is rare and a proportion of mutant BRAF
melanomas are less responsive to the inhibitors, indicative of
inherent resistance.11,14–16 Moreover, the durations of responses
are commonly limited, with most patients relapsing within
1 year, which is indicative of development of acquired drug
resistance.11,14–16 Multiple mechanisms have been shown to
contribute to the resistance of mutant BRAF melanomas to
BRAF inhibitors.11,14–16 These include those mechanisms leading to insufficient inhibition of RAF/MEK/ERK signaling and
those promoting melanoma cell survival and proliferation
alternative to the RAF/MEK/ERK pathway, such as increased
activation of the PI3K/Akt or NF-κB pathways.17–25 Indeed,
combinations of RAF inhibitors and inhibitors of MEK such
as trametinib to further inhibit MEK/ERK signaling have
yielded promising results in clinical trials.26–28 Co-targeting
the PI3K/Akt and RAF/MEK/ERK pathways is also being
evaluated in early clinical studies.23,29
Insulin is known to activate the PI3K/Akt pathway and
thus increases carcinogenesis.30,31 Besides gene mutations of
the major components of the pathway, extracellular stimuli
such as insulin and insulin-like growth factor 1 (IGF-1)
also enhance PI3K/Akt signaling and cause drug resistance.
Indeed, in many types of cancer cells, insulin induces
resistance to chemotherapeutic drugs and may contribute
to poor prognosis, particularly in patients with obesity and
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type II diabetes.32,33 However, the role of insulin in melanoma cell resistance to chemotherapy and targeted therapy
remains less understood. Here we show that insulin attenuates
the therapeutic efficacy of DTIC and the BRAF inhibitor
PLX4720 in melanoma cells, and that this is mediated by
activation of the PI3K/Akt pathway and can be overcome by
PI3K inhibitors and dual inhibitors of PI3K and mammalian
target of rapamycin (mTOR).

Materials and methods
Cell culture and reagents
The mouse melanoma cell line B16 and the human melanoma cell line Mel-RMu described previously were cultured
in Dulbecco’s Modiﬁed Eagle’s Medium containing 5%
fetal calf serum.34 Antibodies against Akt and phospho-Akt
(Ser473) were purchased from Cell Signaling Technology
(Danvers, MA, USA). The PI3K inhibitor LY294002 was
from Calbiochem (Merck KGaA, Darmstadt, Germany).
The dual inhibitor PI3K and mTOR, BEZ-235, was from
Selleckchem (Houston, TX, USA). The antibodies against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
from Ambion (Life Technologies, Carlsbad, CA, USA).
The BRAF inhibitor PLX4720 was from Selleckchem.
Dacarbazine was purchased from Sigma-Aldrich (St Louis,
MO, USA).

Cell viability
Cell viability was determined by MTS assay using Celltiter
96 aqueous one solution cell proliferation assay kit according
to the manufacturer’s instructions (Promega Corporation,
Madison, WI, USA) as described previously.35 In brief, cells
were seeded at 5,000 cells/well onto flat-bottomed 96-well
culture plates and allowed to grow for 24 hours followed by
the desired treatment duration. Cells were then labeled with
the VisionBlueTM reagent and detected by Synergy 2TM multidetection microplate reader (Biotek, Winooski, VT, USA).

Immunoblotting
Immunoblotting was carried out as described previously.35
Labeled bands were detected by Luminata Crescendo
Western horseradish peroxidase substrate (EMD Millipore,
Billerica, MA, USA) and images were captured and the
intensity of the bands was quantitated using an ImageReader
LAS-4000 (Fujifilm Corporation, Tokyo, Japan).

Statistical analysis
Statistical analysis was performed using JMP Statistics
Made VisualTM software (SAS Institute, Cary, NC, USA).
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Student’s t-test was used to assess differences in the values
of different experimental groups. P-values less than 0.05
were considered statistically significant.

Results
Insulin protects melanoma cells against
DTIC-mediated cytotoxicity
We examined the cytotoxic effect of DTIC on the mouse
melanoma cell line B16 that harbored wild-type BRAF
and the human melanoma cell line Mel-RMu that carried
BRAFV600E by treating the cells with the drug at increasing
concentrations for 24 hours.36,37 As shown in Figure 1, DTIC
reduced viability of B16 and Mel-RMu cells in a dosedependent manner irrespective of their BRAF mutational
status. Since DTIC at 25 µg/mL inhibited viability of both
B16 and Mel-RMu cells by approximately 50% (Figure 1).
This concentration was chosen for assays hereafter.
To examine whether insulin protects melanoma cells
from cytotoxicity induced by DTIC, B16 and Mel-RMu cells
were pre-treated with insulin at a range of concentrations for
15 minutes before the addition of DTIC at 25 µg/mL for a
further 24 hours. As shown in Figure 2, even when used at
250 nM, insulin significantly protected Mel-RMu and, to a
lesser extent, B16 cells from DTIC-mediated cytotoxicity.
The survival rates of Mel-RMu and B16 cells were increased
by 40% and 25%, respectively (Figure 2). Notably, insulin at
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Figure 1 Cytotoxicity of DTIC towards melanoma cells.
Notes: B16 mouse melanoma cells and Mel-RMu human melanoma cells were
treated with DTIC at indicated concentrations for 24 hours. Cell viability was
measured by MTS assays and expressed as a relative value of control. The data
shown are the mean ± standard error of three individual experiments.
Abbreviations: DTIC, dacarbazine; MTS, CellTiter 96® aqueous one solution cell
proliferation.
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increased concentrations did not afford any further protection
against DTIC. This may be due to negative cooperativity of
binding of insulin to its receptor.38 Regardless, these results
suggest that circulating insulin in melanoma patients, particularly melanoma patients with obesity, may attenuate the
therapeutic efficacy of chemotherapeutic drugs.

Insulin protects BRAFV600E melanoma cells
from cytotoxicity induced by the mutant
BRAF inhibitor PLX4720
Since Mel-RMu cells are known to harbor BRAFV600E and
are sensitive to the mutant BRAF inhibitor PLX4720,24 we
examined whether insulin similarly protects the cells from
PLX4720-mediated cytotoxicity. B16 mouse melanoma cells
that carry wild-type BRAF and are not sensitive to mutant
BRAF inhibitors were excluded from studies using PLX4720.39
Indeed, insulin at 250 nM significantly inhibited reduction in
viability of Mel-RMu cells induced by PLX4720 (Figure 3).

Insulin activates the PI3K/Akt signalling
pathway in melanoma cell lines
Aberrant activation of the PI3K/Akt pathway is known to
confer resistance of melanoma cells to therapeutic drugs.30,31
We examined whether exposure of melanoma cells to insulin
results in activation of PI3K/Akt signaling. As anticipated,
exposure to insulin increased the levels of phosphorylated
Akt in both B16 and Mel-RMu cells (Figure 4), indicating
increased activation of the PI3K/Akt pathway.

Inhibition of the PI3K/Akt pathway
reverses protection of melanoma cells
against DTIC and/or PLX4720 by insulin
To confirm the role of the PI3K/Akt pathway in insulinmediated protection of melanoma cells from therapeutic
drugs, we pre-treated B16 and Mel-RMu cells with the
PI3K and mTOR dual inhibitor BEZ-235 before the addition of insulin (250 nM) followed by DTIC. While BEZ235 abolished the increase in activation of Akt induced by
insulin in both B16 and Mel-RMu cells (Figure 5A), it also
diminished insulin-mediated protection against cytotoxicity induced by DTIC (Figure 5B). Similarly, BEZ-235 also
significantly inhibited protection of Mel-RMu cells against
PLX4720 by insulin (Figure 5C). Of note, BEZ-235 enhanced
cytotoxicity triggered by PLX4720 alone in Mel-RMu cells
(Figure 5C), consistent with previous reports that inhibition
of the PI3K/Akt pathway sensitizes mutant BRAF melanoma
cells to BRAF inhibitors.40,41
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Figure 2 Insulin protects melanoma cells against DTIC.
Notes: B16 (upper panel) and Mel-RMu (lower panel) cells with or without pretreatment with insulin at indicated concentrations for 15 minutes were treated with DTIC
(25 µg/mL) for a further 24 hours. Cell viability was measured by MTS assays. The data shown are the mean ± standard error of three individual experiments (*P,0.01,
Student’s t-test).
Abbreviations: DTIC, dacarbazine; MTS, CellTiter 96® aqueous one solution cell proliferation.

We also examined whether the PI3K inhibitor
LY294002 similarly reverses protection of melanoma cells
against therapeutic drugs by insulin. As shown in Figure 6A,
LY294002 abolished the insulin-triggered increase in activation of Akt in B16 and Mel-RMu cells. Moreover, similar
to BEZ-235, it also significantly inhibited insulin-mediated
protection of B16 and Mel-RMu cells from DTIC, and protection of Mel-RMu cells from PLX4720 (Figure 6B and C).
Together, these results suggest that activation of the PI3K/Akt
pathways plays a predominant role in protection of melanoma
cells from therapeutic drugs by insulin.
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Figure 3 Insulin protects BRAFV600E melanoma cells against the BRAF inhibitor
PLX4720.
Notes: Mel-RMu cells with or without pretreatment with insulin (250 nM) for
15 minutes were treated with PLX4720 (5 µM) for a further 24 hours. Cell viability
was measured by MTS assays. The data shown are the mean ± standard error of
three individual experiments (*P,0.01, Student’s t-test).
Abbreviations: MTS, CellTiter 96® aqueous one solution cell proliferation; BRAF,
v-Raf murine sarcoma viral oncogene homolog B1.
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Discussion
Resistance of melanoma cells to therapeutic drugs is a major
obstacle in the quest for curative treatment of melanoma.
The response rate to the conventional chemotherapeutic drug
DTIC is only 5%–10%,5 whereas approximately 50%–60%
of patients with mutant BRAF metastatic melanomas
initially respond to the BRAF inhibitor vemurafenib or
Drug Design, Development and Therapy 2014:8
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Figure 4 Insulin activates the PI3K/Akt in melanoma cells.
Notes: Whole cell lysates from B16 and Mel-RMu cells with or without treatment
with insulin (250 nM) for 15 minutes were subjected to Western blot analysis of
phosphorylated Akt, Akt, and GAPDH (as a loading control). The data shown are
representative of three individual experiments.
Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Akt, protein
kinase B.

dabrafenib.11,14–16 Nevertheless, durations of responses to
BRAF inhibitors are commonly limited, with most patients
relapsing within 1 year. 12,15,16 One of the mechanisms
responsible for resistance of melanoma cells to therapeutic
drugs is aberrant activation of the PI3K/Akt pathway due to
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genetic mutations and/or epigenetic deregulation of its major
regulators.42,43 However, the role of extracellular stimuli that
can activate the pathway in drug-resistant melanoma cells
remains less well understood. In this report, we demonstrated
that the addition of insulin enhanced resistance of cultured
melanoma cells to DTIC. In addition, we showed that insulin
also protected mutant BRAF melanoma cells from the BRAF
inhibitor PLX4720. These results suggest that elevated
levels of circulating insulin in melanoma patients, such as
those with obesity and type II diabetes, may compromise
their responses to conventional chemotherapeutic drugs
and agents targeting pro-survival pathways, thus leading to
poor prognosis.
Our study showed that insulin increased activation of
the PI3K/Akt pathway, and that inhibition of the pathway
reversed insulin-mediated protection against DTIC in both
wild-type BRAF B16 cells and BRAFV600E Mel-RMu cells.
In addition, the results also demonstrated that inhibition of
cytotoxicity of PLX4720 by insulin in Mel-RMu cells were
also abolished when PI3K/Akt signaling was blocked. These
results indicate that activation of the PI3K/Akt pathway
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Figure 5 The PI3K and mTOR dual inhibitor BEZ-235 reverses protection of melanoma cells against DTIC and/or PLX4720 by insulin.
Notes: (A) Whole cell lysates from B16 and Mel-RMu cells with or without pretreatment with BEZ-235 (50 nM) for 1 hour followed by exposure to insulin (250 nM) for
a further 15 minutes were subjected to Western blot analysis of phosphorylated Akt, Akt, and GAPDH (as a loading control). The data shown are representative of three
individual experiments. (B) B16 (upper panel) and Mel-RMu (lower panel) cells were pretreated with BEZ-235 (50 nM) for 1 hour before the addition of insulin (250 nM)
for 15 minutes followed by exposure to DTIC (25 µg/mL) for a further 24 hours. Cell viability was measured by MTS assays. The data shown are the mean ± standard error
of three individual experiments (*P,0.01, Student’s t-test). (C) Mel-RMu cells were pretreated with BEZ-235 (50 nM) for 1 hour before the addition of insulin (250 nM) for
15 minutes followed by exposure to PLX4720 (5 µM) for a further 24 hours. Cell viability was measured by MTS assays. The data shown are the mean ± standard error of
three individual experiments (*P,0.01, Student’s t-test).
Abbreviations: DTIC, dacarbazine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Akt, protein kinase B; MTS, CellTiter 96® aqueous one solution cell proliferation.
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Figure 6 The PI3K inhibitor LY294002 reverses protection of melanoma cells against DTIC and/or PLX4720 by insulin.
Notes: (A) Whole cell lysates from B16 and Mel-RMu cells with or without pretreatment with LY294002 (20 µM) for 1 hour followed by exposure to insulin (250 nM) for
a further 15 minutes were subjected to Western blot analysis of phosphorylated Akt, Akt, and GAPDH (as a loading control). The data shown are representative of three
individual experiments. (B) B16 (upper panel) and Mel-RMu (lower panel) cells were pretreated with LY294002 (20 µM) for 1 hour before the addition of insulin (250 nM)
for 15 minutes followed by exposure to DTIC (25 µg/mL) for a further 24 hours. Cell viability was measured by MTS assays. The data shown are the mean ± standard error
of three individual experiments (*P,0.01, Student’s t-test). (C) Mel-RMu cells were pretreated with LY294002 (20 µM) for 1 hour before the addition of insulin (250 nM)
for 15 minutes followed by exposure to PLX4720 (5 µM) for a further 24 hours. Cell viability was measured by MTS assays. The data shown are the mean ± standard error
of three individual experiments (*P,0.01, Student’s t-test).
Abbreviations: DTIC, dacarbazine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Akt, protein kinase B; MTS, CellTiter 96® aqueous one solution cell proliferation.

plays an essential role in drug resistance of melanoma cells
induced by insulin. The PI3K/Akt pathway is a well-known
pro-survival pathway in many cancers.30,31 The pathway is
activated by various growth factors and regulates a broad
range of targets that regulate cell survival, proliferation, and
resistance to therapeutic agents.31 Our results showing that
insulin activates the PI3K/Akt pathway leading to drug resistance reinforce the importance of extracellular stimuli of the
pathway in protection of melanoma cells against treatment.
Insulin is known to bind to insulin receptors, IGF-1 receptors,
and insulin/IGF-1 hybrid receptors to activate PI3K/Akt.40
In addition, it can inhibit the production of IGF-binding
proteins and therefore increase blood levels of IGF-1, a
stronger anti-apoptotic molecule than insulin. Indeed, blood
levels of IGF-1 have been reported to positively associate
with the incidence of melanoma while blood levels of IGFbinding proteins are inversely associated.23 IGF-1 has been
demonstrated to increase survival and growth of melanoma
cells via activation of MAPK and PI3K/Akt pathways.44 It is
highly possible that IGF-1 can also cause drug resistance to
chemotherapeutic agents in melanoma cells. In addition to
insulin, a number of other growth factors that may exist in a
melanoma microenvironment, such as fibroblast growth factor, hepatocyte growth factor, and epithelial growth factor, are
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conceivably involved in drug resistance of melanoma cells,
as they can similarly stimulate PI3K/Akt signaling and other
survival pathways such as the MEK/ERK pathway.
DTIC is a standard drug that is commonly used in the
treatment of metastatic melanoma. Although the initial
response rate is low, the drug is not out of date.4,5 Our
results showing that activation of the PI3K/Akt pathway by
insulin protects melanoma cells from DTIC could partially
explain the low response rate to DTIC, and suggest that the
combinatorial approaches with inhibitors of the PI3K/Akt
pathway and DTIC may increase the therapeutic efficacy.
Combinations of DTIC with other agents have not been
satisfactory.6,8
It is of note that the PI3K inhibitor LY294002 and the
PI3K and mTOR dual inhibitor BEZ-235 decreased the effect
of insulin on protection of melanoma cells against therapeutic
drugs to a similar extent, suggesting that the protective effect
of insulin is mainly mediated by PI3K, although mTOR may
also play a role. Various inhibitors of the PI3K/Akt pathway
and dual inhibitors of PI3K and mTOR are in clinical and/
or preclinical studies, including BEZ-235.45 Our results support combinations of BEZ-235 and other PI3K inhibitors
with clinically available agents for further evaluation. One
of the suitable conditions for such a regime is in the case of

Drug Design, Development and Therapy 2014:8
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patients with elevated serum levels of insulin, such as those
with obesity and type II diabetes.
In summary, we have provided evidence that insulin
protects melanoma cells from the chemotherapeutic drug
DTIC and BRAF inhibitors. In addition, we have shown that
insulin-induced drug resistance is primarily due to activation
of the PI3K/Akt pathway. Our results indicate that combinations of inhibitors of the PI3K/Akt pathway and DTIC or
BRAF inhibitors may be useful to improve the therapeutic
efficacy in the treatment of melanoma, in particular, in
patients with obesity and type II diabetes who have elevated
serum insulin levels.
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